Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedservRegisMAL:MDS 43 EV-to-EBITDA is 5.43 as of Aug. 14, 2026, which is 45% below its 10-year median of 9.86. GuruFocus rates MAL:MDS with a GF Score™ of 43/100 and a GF Value™ of €0.93 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 770 Oil & Gas companies, MedservRegis ranks better than 66.1% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, MedservRegis's enterprise value is €117.4 Mil.
MedservRegis's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €21.6 Mil. Therefore, MedservRegis's EV-to-EBITDA for today is 5.43.
The historical rank and industry rank for MedservRegis's EV-to-EBITDA or its related term are showing as below:
MAL:MDS'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -3.86 Med: 9.86 Max: 376.54
Current: 5.43
During the past 13 years, the highest EV-to-EBITDA of MedservRegis was 376.54. The lowest was -3.86. And the median was 9.86.
MAL:MDS's EV-to-EBITDA is ranked better than 66.1% of 770
companies
in the Oil & Gas industry
Industry Median: 7.555
vs MAL:MDS: 5.43
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
MedservRegis's PE Ratio (TTM) for today is calculated as:
MedservRegis's share price for today is €0.65.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MedservRegis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €0.051.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for MedservRegis's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Oil & Gas Equipment & Services subindustry, MedservRegis's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MedservRegis EV-to-EBITDA vs Oil & Gas Industry
For the Oil & Gas industry and Energy sector, MedservRegis's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where MedservRegis's EV-to-EBITDA falls into.
MedservRegis's current Enterprise Value is €117.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. MedservRegis's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was €21.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MedservRegis (MAL:MDS) has a EV-to-EBITDA of 5.43 as of Aug. 14, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MedservRegis. This is 45% below median its historical median of 9.86. According to the industry distribution chart, MedservRegis ranks #261 out of 770 companies in the Oil & Gas industry, placing it in the top 33.9%.
Is MedservRegis' EV-to-EBITDA too high?
MedservRegis' current EV-to-EBITDA of 5.43 is 45% below median its 10-year median of 9.86. The Oil & Gas industry median EV-to-EBITDA is 7.56. MedservRegis' value of 5.43 is 28.1% below this industry median. Based on the distribution chart, MedservRegis ranks #261 out of 770 companies in the Oil & Gas industry, which is above the industry midpoint. Overall, MedservRegis has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MedservRegis' EV-to-EBITDA compare to SLB and BKR?
According to the Oil & Gas industry distribution chart, MedservRegis ranks #261 out of 770 companies for EV-to-EBITDA. This puts MedservRegis in the upper half of its industry. The industry median EV-to-EBITDA is 7.56. MedservRegis' value of 5.43 is 28.1% below this benchmark. While the company's 10-year median is 9.86 vs. the industry median of 7.56, MedservRegis has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for an Oil & Gas company?
The median EV-to-EBITDA among Oil & Gas companies is 7.56, based on 770 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MedservRegis's current EV-to-EBITDA of 5.43 is 28.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on MedservRegis. For the Oil & Gas industry, the median EV-to-EBITDA is 7.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MedservRegis's current EV-to-EBITDA is 5.43, which is 45% below median its own 10-year median of 9.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MedservRegis stock overvalued right now?
Based on GuruFocus' analysis, MedservRegis (MAL:MDS) is currently considered Possible Value Trap. The stock's GF Value™ is €0.93, compared to a current price of €0.65 — trading 30.1% below its estimated fair value. The current EV-to-EBITDA is 5.43, which is 45% below median its 10-year median of 9.86 and 28.1% below the Oil & Gas industry median of 7.56. MedservRegis' overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For MedservRegis (MAL:MDS), the current EV-to-EBITDA is 5.43 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MedservRegis (MAL:MDS) Overvalued in 2026?
Based on GuruFocus' analysis, MedservRegis stock appears to be undervalued.
The current stock price of €0.65 is trading 30.1% below its estimated GF Value™ of €0.93.
GuruFocus considers MedservRegis to be Possible Value Trap.
Key valuation signals for MAL:MDS:
EV-to-EBITDA: 5.43 (45% below median its 10-year median of 9.86)
GF Value™: €0.93 vs. price of €0.65 (30.1% below fair value)
Industry Position: 28.1% below the Oil & Gas median (#261 of 770)
No single metric tells the full story. See the MAL:MDS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MedservRegis PLC is engaged in providing shore-based logistics to the offshore oil and gas industry and engineering and supply chain management for oil country tubular goods (OCTG) to support the onshore oil and gas industry. Its segment includes Integrated logistics support services; Oil country tubular goods; Trading activity and Photovoltaic farms. The company generates maximum revenue from the Integrated logistics support services segment, that Includes the provision of comprehensive logistical support services to the offshore oil and gas industry from the group's bases in Malta, Cyprus, Egypt, South America, and Africa.
43GF Score
Get the complete analysis for MAL:MDS
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAL:MDS has been successfully added to your 
